441 related articles for article (PubMed ID: 10984562)
1. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
[TBL] [Abstract][Full Text] [Related]
5. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
[TBL] [Abstract][Full Text] [Related]
7. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
[TBL] [Abstract][Full Text] [Related]
11. [Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].
Namiki M; Takami A; Koshida K; Nakao S
Nihon Rinsho; 2003 Sep; 61(9):1607-12. PubMed ID: 14515732
[TBL] [Abstract][Full Text] [Related]
12. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study.
Ishiyama K; Takami A; Suzuki S; Konaka H; Namiki M; Ooi A; Nakao S
Jpn J Clin Oncol; 2009 Dec; 39(12):807-12. PubMed ID: 19770130
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
Childs RW
Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans.
Söderdahl G; Barkholt L; Hentschke P; Mattsson J; Uzunel M; Ericzon BG; Ringdén O
Transplantation; 2003 Apr; 75(7):1061-6. PubMed ID: 12698103
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
18. Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.
Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Herens C; DePrijck B; Fillet G; Beguin Y
Bone Marrow Transplant; 2003 Oct; 32(8):829-34. PubMed ID: 14520430
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
Bay JO; Fleury J; Choufi B; Tournilhac O; Vincent C; Bailly C; Dauplat J; Viens P; Faucher C; Blaise D
Bone Marrow Transplant; 2002 Jul; 30(2):95-102. PubMed ID: 12132048
[TBL] [Abstract][Full Text] [Related]
20. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
